elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Gadodiamide
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Gadodiamide
RIS
0.001
(Research Intensity Score)
Papers
195
Top papers
EVenn: Easy to create repeatable and editable Venn diagrams and Venn networks online
2021 · 405 citations
Stem cell–nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy
2023 · 63 citations
Preclinical Profile of Gadoquatrane
2022 · 61 citations
Differences in hypersensitivity reactions and gadolinium deposition disease/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS
2024 · 19 citations
Physicochemical and Pharmacokinetic Profiles of Gadopiclenol
2019 · 153 citations
Newest papers
Effect of liver fibrosis on gadolinium retention from gadodiamide, gadobutrol, and gadoxetate disodium in rats
2026
Comparative characteristics of acute toxicity of gadolinium-containing drugs for MRI diagnostics
2026
Gold Nanoparticle-Enabled Fluorescence Sensing of Gadolinium-Based Contrast Agents in Urine
2025 · 6 citations
Symptoms Associated With Gadolinium Exposure
2025 · 5 citations
Identifying a potential role of immune cells in gadolinium deposition within the brain
2025 · 3 citations
A sample from the 100 top papers behind Gadodiamide.
Create a free account to browse them all →
Gadodiamide's history
Research intensity over time
Explore Gadodiamide's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Gadodiamide's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link